KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Invested Capital (2017 - 2026)

Amneal Pharmaceuticals has reported Invested Capital over the past 9 years, most recently at -$13.0 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 73.77% year-over-year to -$13.0 million; the TTM value through Dec 2025 reached -$13.0 million, up 73.77%, while the annual FY2025 figure was -$13.0 million, 73.77% up from the prior year.
  • Invested Capital for Q4 2025 was -$13.0 million at Amneal Pharmaceuticals, down from $2.5 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $3.1 billion in Q4 2021 and troughed at -$49.4 million in Q4 2024.
  • A 5-year average of $1.8 billion and a median of $2.3 billion in 2024 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: skyrocketed 572.29% in 2022 and later tumbled 160.97% in 2024.
  • Year by year, Invested Capital stood at $3.1 billion in 2021, then fell by 8.83% to $2.8 billion in 2022, then tumbled by 97.11% to $81.0 million in 2023, then tumbled by 160.97% to -$49.4 million in 2024, then surged by 73.77% to -$13.0 million in 2025.
  • Business Quant data shows Invested Capital for AMRX at -$13.0 million in Q4 2025, $2.5 billion in Q3 2025, and $2.1 billion in Q2 2025.